Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (NCT04136353)
DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801): A Randomised Phase 3 Double-blind, Placebo-controlled Trial of Adding Darolutamide to Androgen Deprivation Therapy and Definitive or Salvage Radiation in Very High Risk, Clinically Localised Prostate Cancer
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to determine the effectiveness of darolutamide as part of adjuvant androgen deprivation therapy (ADT) with a luteinising hormone releasing hormone analogue (LHRHA) in men having radiation therapy for localised prostate cancer at very high risk of recurrence.
Who can join: Review the eligibility criteria below.
Location: Dana-Farber Cancer Institute — Boston, Massachusetts
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (93 Sites)
Showing the first 25 of 93 sites.
- Dana-Farber Cancer Institute — Boston, Massachusetts
- Dana Farber Cancer Institute - St. Elizabeth's — Brighton, Massachusetts
- Lahey Hospital and Medical Center — Burlington, Massachusetts
- Dana Farber Cancer Institute - Milford — Milford, Massachusetts
- XCancer Omaha/Urology Cancer Center — Omaha, Nebraska
- Memorial Sloan Kettering Basking Ridge — Basking Ridge, New Jersey
- New Jersey Urology Saddle Brook — Clifton, New Jersey
- Memorial Sloan Kettering Monmouth — Middletown, New Jersey
- Memorial Sloan Kettering Bergen — Montvale, New Jersey
- New Jersey Urology Voorhees — Voorhees Township, New Jersey
- New Mexico Oncology and Hematology Specialists — Albuquerque, New Mexico
- Memorial Sloan Kettering Commack — Commack, New York
- Memorial Sloan Kettering Westchester — Harrison, New York
- New York University Langone Long Island — Mineola, New York
- New York University Langone Medical Center — New York, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Memorial Sloan Kettering Nassau — Uniondale, New York
- Dayton Physicians Network — Kettering, Ohio
- Seattle Cancer Care Alliance — Seattle, Washington
- Border Medical Oncology Research Unit — Albury, New South Wales
- Gosford Hospital — Gosford, New South Wales
- GenesisCare Newcastle — Newcastle, New South Wales
- Calvary Mater Newcastle — Newcastle, New South Wales
- Shoalhaven District Memorial Hospital — Nowra, New South Wales
- St Vincent's Public Hospital — Sydney, New South Wales
📞 Contact the Study Coordinator
Phone: (877) 338-7425
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Prostate Cancer
- A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC — Homewood, Alabama
- A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described — Homewood, Alabama
- Stereotactic Ablative Radiation Therapy for Prostate Cancer — Charleston, South Carolina
- A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer — Basking Ridge, New Jersey
- A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer — Phoenix, Arizona
- Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer — Baltimore, Maryland
Explore by condition: All Prostate Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.